UpcomingPDUFA target action date

Quimilza (imsidolimab)

Vanda Pharmaceuticals (VNDA)

Marketer take

Would be a second biologic for generalized pustular psoriasis after Spevigo, so dermatologists will hear differentiation messaging in a rare disease where recognizing GPP flares is still a core education need.

Sponsor company
Vanda Pharmaceuticals (VNDA)
Indication
Generalized pustular psoriasis (GPP)
Therapeutic area
Dermatology, Rare disease
Event
PDUFA target action date
Date
Dec 12, 2026
Status
Upcoming
Source
SEC filing
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move